This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
A. Avenell , J. Broom , T. J. Brown , A. Poobalan , L. Aucott , S. C. Steran , W. C. Smith , R. T. Jung , M. K. Campbell A. M. Grant (2004), ‘Systematic review of the long-term effects and economic consequences of treatments of obesity and implications for health improvement’, Health Technology Assessment, 8(iii–iv): 1–182.
A. Bobinac , N. J. A. van Exel , F. F. H. Rutten W. B. F. Brouwer (2010), ‘Willingness to pay for a QALY: the individual approach’, Value in Health, 13(8): 1046–1055.
A. Bobinac , W. B. F. Brouwer N. J. A. van Exel (2011b), ‘Societal discounting and growing healthy life expectancy – an empirical investigation’, Health Economics, 20(1): 111–119.
W. B. F. Brouwer , L. W. Niessen , M. J. Postma F. F. H. Rutten (2005), ‘Need for differential discounting of costs and health effects in cost effectiveness analyses’, British Medical Journal, 331: 446–448.
W. B. F. Brouwer , N. J. A. van Exel , P. H. M. van Baal J. J. Polder (2007), ‘Economics and public health: engaged to be happily married!’, European Journal of Public Health, 17: 122–123.
W. B. F. Brouwer , N. J. A. van Exel , R. Baker C. Donaldson (2008), ‘The new myth: the social value of a QALY’, PharmacoEconomics, 26: 1–4.
K. Claxton , M. Paulden , H. Gravelle , W. B. F. Brouwer A. J. Culyer (2011), ‘Discounting and decision making in the economic evaluation of health-care technologies’, Health Economics 20: 2–15.
K. Claxton , M. Sculpher M. Drummond (2002), ‘A rational framework for decision making by the National Institute for Clinical Excellence (NICE)’, Lancet, 360: 711–715.
E. W. de Bekker-Grob , J. J. Polder , J. P. Mackbach W. J. Meerding (2007), ‘Towards a comprehensive estimate of national spending on prevention’, BMC Public Health, 7: 252.
H.-G. Eichler , S. X. Kong , W. C. Gerth , P. Mavros B. Jönsson (2004), ‘Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness tresholds expected to emerge?’, Value in Health, 7: 518–528.
T. L. Feenstra , H. H. Hamberg-van Reenen , R. T. Hoogenveen M. P. Rutten-van Molken (2005), ‘Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modelling study’, Value in Health, 8: 178–190.
T. L. Feenstra , P. H. M. van Baal , A. Gandjour W. B. F. Brouwer (2008), ‘Future costs in economic evaluation: a comment on Lee’, Journal of Health Economics, 27: 1645–1649.
A. M. Garber C. E. Phelps (1997), ‘Economic foundations of cost-effectiveness analysis’, Journal of Health Economics, 16: 1–31.
H. Gravelle , W. B. F. Brouwer , L. W. Niessen , M. J. Postma F. F. H. Rutten (2007), ‘Discounting in economic evaluations: stepping forward towards optimal decision rules’, Health Economics, 16: 307–317.
H. Gravelle D. Smith (2001), ‘Discounting for health effects in cost-benefit and cost-effectiveness analysis’, Health Economics, 10: 587–599.
D. W. Haslam W. P. T. James (2005), ‘Obesity’, Lancet, 366: 1197–1209.
W. H. Herman , T. J. Hoerger , M. Brandle , M. Hicks , S. Sorensen , P. Zhang , R. F. Hamman , R. T. Ackermann , M. M. Engelgau R. E. Ratner , Diabetes Prevention Program Research Group (2005), ‘The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance’, Annals of Internal Medicine, 142: 323–332.
R. A. Hirth , M. E. Chernew , E. Miller , A. M. Fendrick W. G. Weissert (2000), ‘Willingness to pay for a quality-adjusted life year: in search of a standard’, Medical Decision Making, 20: 332–342.
M. Johannesson (2001), ‘Should we aggregate relative or absolute changes in QALYs?’, Health Economics, 10: 573–577.
S. E. Johansson J. Sundquist (1999), ‘Change in lifestyle factors and their influence on health status and all-cause mortality’, International Journal of Epidemiology, 28: 1073–1080.
E. B. Keeler S. Cretin (1983), ‘Discounting of life-saving and other non-monetary effects’, Manage Science, 29: 300–306.
M. A. Koopmanschap , F. F. H. Rutten , B. M. van Ineveld L. van Roijen (1995), ‘The friction cost method for measuring indirect costs of disease’, Journal of Health Economics, 14: 171–189.
C. McCabe , K. Claxton A. J. Culyer (2008), ‘The NICE cost-effectiveness threshold: what it is and what that means’, PharmacoEconomics, 26: 733–744.
D. Meltzer (1997), ‘Accounting for future costs in medical cost-effectiveness analysis’, Journal of Health Economics, 16: 33–64.
D. Meltzer M. Johannesson (1999), ‘Inconsistencies in the “societal perspective” on costs of the panel on cost-effectiveness in health and medicine’, Medical Decision Making, 19: 371–377.
E. Nord (2005), ‘Concerns for the worse off: fair innings versus severity’, Social Science & Medicine, 60: 257–263.
J. A. Nyman (2004), ‘Should the consumption of survivors be included as a cost in cost-utility analysis?’, Health Economics, 13: 417–427.
R. H. Lee (2008), ‘Future costs in cost effectiveness analysis’, Journal of Health Economics, 27: 809–818.
D. R. Rappange , W. B. F. Brouwer , F. F. H. Rutten P. H. M. van Baal (2010), ‘Lifestyle intervention: from cost savings to value for money’, Journal of Public Health, 32: 440–447.
D. R. Rappange , P. H. M. van Baal , N. J. A. van Exel , T. L. Feenstra , F. F. H. Rutten W. B. F. Brouwer (2008), ‘Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?’, PharmacoEconomics, 26: 815–830.
M. D. Rawlins A. J. Culyer (2004), ‘National institute for clinical excellence and its value jugdements’, British Medical Journal, 329: 224–227.
E. T. Ronckers , W. Groot A. J. H. A. Ament (2005), ‘Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness’, Medical Decision Making, 25: 437–448.
S. Saha , U.-G. Gerdtham P. Johansson (2010), ‘Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases’, International Journal of Environmental Research and Public Health, 7: 3150–3195.
J. Schreyögg , T. Stargardt , M. Velasco-Garrido R. Busse (2005), ‘Defining the “health benefit basket” in nine european countries: evidence from the European Union Health BASKET project’, European Journal of Health Economics, 6, (Supplement 1): 2–10.
E. A. Stolk , W. B. F. Brouwer J. J. V. van Busschbach (2002), ‘Rationalising rationing: economic and other considerations in the debate about funding of Viagra’, Health Policy, 59: 53–63.
E. A. Stolk , G. van Donselaar , W. B. F. Brouwer J. J. V. van Busschbach (2004), ‘Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall’, PharmacoEconomics, 22: 1097–1107.
E. A. Stolk , A. de Bont , A. R. van Halteren , R. J. Bijlmer M. J. Poley (2009), ‘Role of health technology assessment in shaping the benefits package in the Netherlands’, Expert Reviews of Pharmacoeconomics & Outcomes Research, 9: 85–94.
E. A. Stolk , S. J. Pickee , A. H. J. A. Ament J. J. V. Busschbach (2005), ‘Equity in health care prioritisation: an empirical inquiry into social value’, Health Policy, 74: 343–355.
P. H. M. van Baal , T. L. Feenstra , R. T. Hoogenveen , G. A. de Wit W. B. F. Brouwer (2007), ‘Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a “perfect” cost-utility ratio’, Health Economics, 16: 421–433.
P. H. M. van Baal , J. J. Polder , R. T. Hoogenveen , P. M. Engelfriet , H. C. Boshuizen , T. L. Feenstra , G. A. de Wit W. B. F. Brouwer (2008), ‘Prevention no cure for rising expenditures: lifetime medical costs of obesity’, PLoS Medicine, 5(2): e29 (0242–0249).
M. C. Weinstein W. B. Stason (1977), ‘Foundations of cost-effectiveness analysis for health and medical practices’, New England Journal of Medicine, 296: 716–721.
A. Williams (1997), ‘Intergenerational equity: an exploration of the fair innings argument’, Health Economics, 6: 117–132.